vida: extract claims from 2026-03-lancetpsychiatry-glp1-mental-illness-swedish-cohort

- Source: inbox/queue/2026-03-lancetpsychiatry-glp1-mental-illness-swedish-cohort.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap.md

@@ -11,7 +11,7 @@ sourced_from: health/2025-truveta-ispor-glp1-discontinuation-reasons.md
 scope: correlational
 sourcer: Truveta Research
 supports: ["behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
-related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-persistence-improves-with-specialist-care-supporting-obesity-medicine-infrastructure", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations"]
+related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-persistence-improves-with-specialist-care-supporting-obesity-medicine-infrastructure", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-eating-disorder-risk-doubles-with-prior-mental-health-history"]
 ---
 
 # GLP-1 discontinuation is 12 percent higher among patients with psychiatric medication history creating an access-adherence trap where highest-need populations have lowest persistence
@@ -31,3 +31,10 @@ Concurrent prescribing analysis shows OR 4.45 for suicidal ideation reports with
 **Source:** MDPI Nutrients PMC12694361
 
 Review identifies eating disorder history, perfectionism, OCD traits, and emotion regulation deficits as primary risk factors for GLP-1 adverse psychiatric outcomes. This extends the psychiatric comorbidity discontinuation pattern by specifying which psychiatric phenotypes create highest risk: restrictive eating disorders and obsessive-compulsive spectrum conditions rather than psychiatric comorbidity in general.
+
+
+## Extending Evidence
+
+**Source:** Lancet Psychiatry 2026, Karolinska Institutet
+
+Swedish study population (95,490 people with pre-existing depression/anxiety) demonstrates that psychiatric comorbidity is both a predictor of GLP-1 prescribing AND a population where the drug shows large protective effects (42% reduction in worsening). This creates a paradox: the population most likely to benefit faces highest discontinuation risk.

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -11,7 +11,7 @@ sourced_from: health/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.m
 scope: structural
 sourcer: NEDA/ANAD
 supports: ["ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
-related: ["the-mental-health-supply-gap-is-widening-not-closing", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "neda", "anad", "glp1-eating-disorder-screening-lacks-reimbursement-infrastructure-despite-identified-risk-population"]
+related: ["the-mental-health-supply-gap-is-widening-not-closing", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "neda", "anad", "glp1-eating-disorder-screening-lacks-reimbursement-infrastructure-despite-identified-risk-population", "glp1-eating-disorder-screening-protocol-scoff-plus-history-plus-behavioral-assessment-recommended-for-pre-treatment-risk-stratification", "glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population"]
 ---
 
 # GLP-1 eating disorder screening gap is structural capacity failure not clinical knowledge deficit because professional society guidance requires tri-specialist care teams unavailable in primary care settings where most prescriptions originate
@@ -73,3 +73,10 @@ Dr. DeCaro and Dr. Dennis provide clinical expert consensus that screening proto
 **Source:** STAT News, April 27, 2026
 
 Expert assessment that healthcare system is 'unprepared for this coming wave' of eating disorder cases suggests infrastructure gap extends beyond screening protocols to treatment capacity. The 420,000 person projection (1.28% of potential GLP-1 user population) represents scale that would overwhelm existing eating disorder treatment infrastructure.
+
+
+## Extending Evidence
+
+**Source:** APA Monitor on Psychology, July/August 2025
+
+APA Monitor coverage in July 2025 signals that the psychological professional community formally engaged with GLP-1 mental health effects 9 months before mainstream public awareness. Despite this early professional recognition, no APA clinical practice guidelines on GLP-1 prescribing or monitoring existed as of 2026, confirming the gap is structural capacity (lack of formal protocols and reimbursement) rather than clinical knowledge (practitioners were aware).

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -116,3 +116,10 @@ Review confirms that GLP-1 RAs reduce binge eating disorder episodes through mes
 **Source:** Multiple clinicians (Washington Post, KTLA, Washington Times, April 2026)
 
 The same VTA dopamine circuit suppression that makes GLP-1 effective for addiction also produces broader anhedonia affecting social activities, sex, music, and pleasure generally — clinicians report patients experiencing 'emotional flattening' where they recognize positive moments but feel less excitement or connection. This suggests the mesolimbic dopamine modulation is not addiction-specific but affects general reward sensitivity.
+
+
+## Supporting Evidence
+
+**Source:** Lancet Psychiatry 2026, Karolinska Institutet
+
+Swedish national cohort (n=95,490) shows 47% reduction in substance use disorder worsening during semaglutide use periods using within-individual design that eliminates confounding. Effect size is consistent with mesolimbic dopamine mechanism and extends beyond alcohol to broader SUD category.

domains/health/semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism.md

@@ -31,3 +31,10 @@ VigiBase disproportionality analysis shows semaglutide-specific signals for depr
 **Source:** VigiBase semaglutide-specific analysis
 
 VigiBase data shows semaglutide additional psychiatric signals beyond eating disorders: depressed mood disorders (aROR 1.70), suicidality (aROR 1.45), anxiety (aROR 1.26). These signals are weaker than eating disorder signal (aROR 6.80) but suggest psychiatric effects are multi-dimensional, not uniformly protective.
+
+
+## Supporting Evidence
+
+**Source:** Lancet Psychiatry 2026, Karolinska Institutet
+
+Within-individual design in Swedish cohort (n=95,490) confirms 44% reduction in depression worsening (HR 0.56, 95% CI 0.44-0.71) during semaglutide use periods. Design eliminates time-invariant confounding that matched cohort studies cannot address.

domains/health/semaglutide-reduces-psychiatric-worsening-42-percent-within-individual-design.md

@@ -0,0 +1,20 @@
+---
+type: claim
+domain: health
+description: Swedish national cohort study using within-individual design eliminates time-invariant confounding and shows large protective psychiatric effects during semaglutide use periods
+confidence: likely
+source: Lancet Psychiatry 2026, Karolinska Institutet, n=95,490
+created: 2026-05-06
+title: "Semaglutide reduces worsening of depression, anxiety, and substance use disorder by 40-50% in people with pre-existing mental illness through within-individual comparison"
+agent: vida
+sourced_from: health/2026-03-lancetpsychiatry-glp1-mental-illness-swedish-cohort.md
+scope: causal
+sourcer: Lancet Psychiatry / Karolinska Institutet
+supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"]
+challenges: ["medical-care-explains-only-10-20-percent-of-health-outcomes"]
+related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations"]
+---
+
+# Semaglutide reduces worsening of depression, anxiety, and substance use disorder by 40-50% in people with pre-existing mental illness through within-individual comparison
+
+A Swedish national registry study published in Lancet Psychiatry (March 2026) used within-individual stratified Cox models to compare psychiatric outcomes during periods when the same person was ON versus OFF semaglutide. This design eliminates all time-invariant confounding including baseline psychiatric severity, comorbidities, and social circumstances. Among 95,490 people with pre-existing depression and/or anxiety, semaglutide use was associated with 42% lower risk of composite psychiatric worsening (HR 0.58). Specific outcomes: depression worsening HR 0.56 (44% reduction), anxiety worsening HR 0.62 (38% reduction), substance use disorder worsening HR 0.53 (47% reduction), and self-harm 47% reduction. Liraglutide showed weaker effects at 18% reduction (HR 0.82). The within-individual design is the strongest quasi-experimental approach available in observational epidemiology for this question because it strips away the confounding by indication that plagues matched cohort studies. The magnitude of effect (40-50% reductions) exceeds most approved psychiatric medications for these conditions. This finding directly contradicts the 195% increased MDD risk signal from matched cohort studies by demonstrating that selection bias—people prescribed GLP-1s have more baseline psychiatric comorbidity—explains the apparent risk increase. The FDA meta-analysis of 91 RCTs (107,910 patients) showing no increased psychiatric risk converges with this Swedish finding, while the matched cohort diverges due to methodological limitations.

domains/health/within-individual-design-resolves-glp1-psychiatric-confounding-by-indication.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: "The 195% MDD risk increase in matched cohorts reflects selection bias—people prescribed GLP-1s have worse baseline mental health—while within-individual comparison shows protective effects"
+confidence: likely
+source: Lancet Psychiatry 2026 Swedish study vs Nature Scientific Reports matched cohort
+created: 2026-05-06
+title: Within-individual study designs resolve GLP-1 psychiatric safety divergence by eliminating confounding by indication that creates spurious risk signals in matched cohort studies
+agent: vida
+sourced_from: health/2026-03-lancetpsychiatry-glp1-mental-illness-swedish-cohort.md
+scope: structural
+sourcer: Lancet Psychiatry / Karolinska Institutet
+related: ["glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-eating-disorder-causality-expert-divergence-reflects-evidence-gap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "glp1-eating-disorder-risk-doubles-with-prior-mental-health-history", "glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific"]
+---
+
+# Within-individual study designs resolve GLP-1 psychiatric safety divergence by eliminating confounding by indication that creates spurious risk signals in matched cohort studies
+
+The apparent divergence in GLP-1 psychiatric safety evidence—matched cohort studies showing 195% increased MDD risk versus RCTs and within-individual studies showing protective or neutral effects—is resolved by understanding confounding by indication. The Swedish Lancet Psychiatry study (March 2026) used within-individual stratified Cox models comparing the same person's psychiatric outcomes during periods ON versus OFF semaglutide. This design eliminates all time-invariant confounding including baseline psychiatric severity, unmeasured comorbidities, and social circumstances that propensity score matching cannot fully capture. The finding of 42% reduced psychiatric worsening during semaglutide use periods directly contradicts the matched cohort signal and demonstrates that the 195% MDD risk increase reflects selection bias: people prescribed GLP-1s for obesity have systematically worse baseline mental health than matched controls, even after propensity score adjustment. The FDA meta-analysis of 91 placebo-controlled RCTs (107,910 patients) showing no increased psychiatric risk converges with the within-individual finding, while matched cohort studies diverge due to residual confounding. This establishes a methodological hierarchy: within-individual designs and RCTs should dominate inference over matched cohort studies when confounding by indication is structurally present. The resolution has major implications for GLP-1 prescribing guidelines and psychiatric screening protocols.

inbox/archive/health/2025-07-apa-monitor-glp1-mental-health-effects.md

@@ -7,10 +7,13 @@ date: 2025-07-01
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-06
 priority: medium
 tags: [GLP-1, semaglutide, mental-health, anhedonia, depression, psychiatric-safety, APA, psychology]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-03-lancetpsychiatry-glp1-mental-illness-swedish-cohort.md

@@ -7,10 +7,13 @@ date: 2026-03-22
 domain: health
 secondary_domains: []
 format: research-article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-06
 priority: high
 tags: [GLP-1, semaglutide, mental-health, depression, anxiety, substance-use-disorder, within-individual-design, Swedish-cohort, psychiatric-safety, divergence]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content